[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562245":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo blood sample collection, complete surveys, and have their medical records reviewed on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":22,"role":23},"Catherine E. Martin, PharmD, RPh","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[31],{"facility":22,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-92.4699,44.02163,{"lat":42,"lon":41},[45,46,48],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":47,"role":27,"phone":10,"phoneExt":10,"email":10},"Alexis Kuhn, PharmD, RPh",{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100562245","a-study-to-determine-number-of-patients-who-develop-high-ammonia-levels-after-receiving-recombinant-erwinia-asparaginase-100562245",false,"NCT06600659","A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase","A Pilot Study to Establish Incidence and Characteristics of Patients at Risk for Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase","Inclusion Criteria:\n\n* Followed by pediatric hematology\u002Foncology\n* Receiving recombinant Erwinia asparaginase for treatment of malignancy\n\nExclusion Criteria:\n\n* Patients \\\u003C 1 year of age\n* Patients who have previously received recombinant Erwinia asparaginase within the past two weeks","ALL","1 Year",{"count":61,"type":62},10,"ESTIMATED","OBSERVATIONAL","This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.",[66,67],"Hematopoietic and Lymphatic System Neoplasm","Acute Lymphobkastic Leukemia","2026-02-04",{"date":70,"type":71},"2026-02-06","ACTUAL",{"date":73,"type":71},"2023-11-02",{"date":75,"type":62},"2026-12-01",{"name":5,"class":6},1]